OSLO, Norway--(BUSINESS WIRE)--DiaGenic has received notice of allowance of the family 3 patent application in Japan ( 2007-514130). The claims allowed cover the use of some important gene sequences in blood sample for detection and monitoring of breast cancer. The patent will be valid until 2025. Family 3 patents have earlier been granted in US and Europe.
